May 10, 2025

Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

52 minutes

Featuring an interview with Dr John P Leonard, including the following topics:

First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00)
Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27)
Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30)
Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24)
Practical considerations for the administration of mosunetuzumab (22:03)
Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33)
Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27)
Risk of infection for patients receiving bispecific antibodies (33:23)
Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21)
Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23)
Myths and misperceptions about the management of DLBCL, FL and MCL (47:29)

CME information and select publications

...more

By Dr Neil Love

4.6

112112 ratings

May 10, 2025

52 minutes

Featuring an interview with Dr John P Leonard, including the following topics:

First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00)
Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27)
Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30)
Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24)
Practical considerations for the administration of mosunetuzumab (22:03)
Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33)
Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27)
Risk of infection for patients receiving bispecific antibodies (33:23)
Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21)
Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23)
Myths and misperceptions about the management of DLBCL, FL and MCL (47:29)